immunotherapy-2019-scientifictracks

9 / 9

Page 21
May 22-23, 2019 | Rome, Italy
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
IMMUNOLOGY
AND CANCER THERAPY
2nd Global Summit on
Immunotherapy 2019 Immunology Case Reports | Volume 3
EFFECTIVE IN VIVO THERAPEUTIC IGG ANTIBODY AGAINST VP3 OF ENTEROVIRUS 71
WITH RECEPTOR-COMPETING ACTIVITY
Fang He1,4, Qiang Jia1, Qingyong Ng1, Wenjie Chin2, Tao Meng1, Vincent Tak Kwong Chow3, Cheng-I
Wang 2 and Jimmy Kwang1,3
1 Temasek Life Sciences Laboratory, Republic of Singapore
2 Agency for Science Technology and Research, Singapore
3 National University of Singapore, Republic of Singapore
4 Zhejiang University, China
Passive immunization is an effective option for treatment against hand, foot and mouth disease caused by
EV71, especially with cross-neutralizing IgG monoclonal antibodies. In this study, an EV71-specific IgG2a
antibody designated 5H7 was identified and characterized. 5H7 efficiently neutralizes the major EV71 geno-
groups (A, B4, C2 and C4). The conformational epitope of 5H7 was mapped to the highly conserved amino acid
position 74 on VP3 capsid protein using escape mutants. Neutralization with 5H7 is mediated by the inhibition
of viral attachment, as revealed by virus-binding and post-attachment assays. In a competitive pull-down assay
with SCARB2, 5H7 blocks the receptor-binding site on EV71 for virus neutralization. Passive immunization of
chimeric 5H7 protected 100% of two-week-old AG129 mice from lethal challenge with an EV71 B4 strain for
both prophylactic and therapeutic treatments. In contrast, 10D3, a previously reported neutralizing antibody
that takes effect after virus attachment, could only confer prophylactic protection. These results indicate that
efficient interruption of viral attachment is critical for effective therapeutic activity with 5H7. This report doc-
uments a novel universal neutralizing IgG antibody for EV71 therapeutics and reveals the underlying mecha-
nism.
Fang He et al., Immunol Case Rep 2019, Volume 3
Fang He is from Institute of Preventive Veterinary Medicine, College of Animal Sciences of Zhejiang University, China. Her research
mainly focuses on vaccine and antibody development against multiple human and animal infectious diseases, including influenza,
HFMD and major swine diseases. She has published over 40 research articles in SCI top journals mostly as first or corresponding
author in Journal of Virology and Journal of Proceedings of the National Academy of Sciences of the United States of America.
BIOGRAPHY